Company records / cellcentric.com
CellCentric CellCentric (cellcentric.com ): 4 changes recorded in its website history since April 2008. Homepage last checked 5 November 2026.
First recorded website Recorded changes Messaging history Cite this record Report a correction Recorded changes Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
Hiring Between 3 November 2025 and 13 June 2026 Added a careers page.
Observed on the company’s website; business claims are not independently verified.
Headline Between 21 January 2021 and 19 July 2022
Before First-in-class p300/CBP inhibitor to treat specific cancers
After We are developing inobrodib, a new drug to benefit people with cancer
Observed on the company’s website; business claims are not independently verified.
Funding Between 18 February 2014 and 16 July 2016 Announced on its homepage: “CellCentric secures funding to take its prostate cancer programme to IND.”.
Observed on the company’s website; business claims are not independently verified.
Headline Between 18 August 2010 and 25 September 2012
Before Unlocking Epigenetics
After Focused Epigenetic Drug Discovery
Observed on the company’s website; business claims are not independently verified.
First recorded website Observed 19 April 2008
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself CellCentric - Cellcentric prioritizes novel epigenetic targets and develops screens and hits
archived page Link to first observation
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
November 2025 – November 2026 · 5 captures · latest observed messaging CellCentric – The p300/CBP inhibitor company This wording observed 5 November 2026.
Inspect 5 captures in this group 3 November 2025 · CellCentric – The p300/CBP inhibitor company archived page 13 June 2026 · CellCentric – The p300/CBP inhibitor company archived page 7 October 2026 · CellCentric – The p300/CBP inhibitor company archived page 7 October 2026 · CellCentric – The p300/CBP inhibitor company archived page 5 November 2026 · CellCentric – The p300/CBP inhibitor company current website Historical capture not publicly available Seen July 2022 · 1 capture We are developing inobrodib, a new drug to benefit people with cancer This wording observed 19 July 2022.
Seen January 2021 · 1 capture First-in-class p300/CBP inhibitor to treat specific cancers This wording observed 21 January 2021.
September 2012 – February 2014 · 2 captures Drug Discovery CellCentric�s lead programme targets a deubiquitinase for cancer therapy.
This wording observed 18 February 2014.
Inspect 2 captures in this group Seen August 2010 · 1 capture Unlocking Epigenetics CellCentric has a dominant discovery platform in epigenetics
This wording observed 18 August 2010.
Seen April 2008 · 1 capture CellCentric - Cellcentric prioritizes novel epigenetic targets and develops screens and hits This wording observed 19 April 2008.
Cite this record StartupHistory, “CellCentric” company record, https://startuphistory.org/c/cellcentric.com
Machine-readable: /c/cellcentric.com.json . How changes are found: method .